Organon (OGN) Divestments (2020 - 2026)

Organon (OGN) recorded quarterly Divestments of $433.0 million in Q1 2026, up 43200.0% quarter-over-quarter from $1.0 million in Q4 2020.

Organon (OGN) Divestments (2020 - 2026) Analysis & Trends

Organon's Divestments history runs 2 years deep, the most recent figure standing at $433.0 million for Q1 2026.

In Q1 2026, Divestments changed N/A year-over-year to $433.0 million; the TTM figure through Mar 2026 stood at $433.0 million (changed N/A YoY), while the FY2020 annual figure was -$8.0 million, up 42.86% from the prior year.
Divestments was $433.0 million for Q1 2026 at Organon, up from $1.0 million in the prior quarter.
In the past five years, Divestments ranged from a high of $433.0 million in Q1 2026 to a low of $433.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Gsk	92,134,969.93 Bn	92,134,964.97 Bn	7.76 Bn	330.30 Mn
2	Eli Lilly	1,027.45 Bn	1,022.17 Bn	16.22 Bn	-
3	Johnson & Johnson	559.08 Bn	537.03 Bn	15.96 Bn	-
4	AbbVie	394.75 Bn	385.40 Bn	10.78 Bn	-
5	Merck	295.12 Bn	289.47 Bn	12.09 Bn	-
6	Amgen	186.65 Bn	174.61 Bn	5.87 Bn	-
7	Gilead Sciences	159.22 Bn	151.50 Bn	5.52 Bn	-
8	Pfizer	146.00 Bn	133.23 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	113.22 Bn	102.77 Bn	8.07 Bn	312.00 Mn
10	Organon	3.49 Bn	2.37 Bn	783.00 Mn	433.00 Mn

Download Data